Value of infliximab (Remicade (R)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group

F. Baron; S. Suciu; S. Amadori; P. Muus; H. Zwierzina; C. Denzlinger; M. Delforge; A. Thyss; D Selleslag; K. Indrak; G.J. Ossenkoppele; T.M. de Witte

doi:https://doi.org/10.3324/haematol.2011.044347

Value of infliximab (Remicade (R)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group

F. Baron, S. Suciu, S. Amadori, P. Muus, H. Zwierzina, C. Denzlinger, M. Delforge, A. Thyss, D Selleslag, K. Indrak, G.J. Ossenkoppele, T.M. de Witte

Hematology (VUmc)

Research output: Contribution to journal › Article › Academic › peer-review

21 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	529-533
Journal	Haematologica
Volume	97
Issue number	4
DOIs	https://doi.org/10.3324/haematol.2011.044347
Publication status	Published - 2012

Access to Document

https://doi.org/10.3324/haematol.2011.044347

Cite this

Baron, F., Suciu, S., Amadori, S., Muus, P., Zwierzina, H., Denzlinger, C., Delforge, M., Thyss, A., Selleslag, D., Indrak, K., Ossenkoppele, G. J., & de Witte, T. M. (2012). Value of infliximab (Remicade (R)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group. Haematologica, 97(4), 529-533. https://doi.org/10.3324/haematol.2011.044347

@article{d4b95bdf9b934a2a8990c58e6b142d60,

title = "Value of infliximab (Remicade (R)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group",

author = "F. Baron and S. Suciu and S. Amadori and P. Muus and H. Zwierzina and C. Denzlinger and M. Delforge and A. Thyss and D Selleslag and K. Indrak and G.J. Ossenkoppele and {de Witte}, T.M.",

year = "2012",

doi = "https://doi.org/10.3324/haematol.2011.044347",

language = "Undefined/Unknown",

volume = "97",

pages = "529--533",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "4",

}

Baron, F, Suciu, S, Amadori, S, Muus, P, Zwierzina, H, Denzlinger, C, Delforge, M, Thyss, A, Selleslag, D, Indrak, K, Ossenkoppele, GJ & de Witte, TM 2012, 'Value of infliximab (Remicade (R)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group', Haematologica, vol. 97, no. 4, pp. 529-533. https://doi.org/10.3324/haematol.2011.044347

TY - JOUR

T1 - Value of infliximab (Remicade (R)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group

AU - Baron, F.

AU - Suciu, S.

AU - Amadori, S.

AU - Muus, P.

AU - Zwierzina, H.

AU - Denzlinger, C.

AU - Delforge, M.

AU - Thyss, A.

AU - Selleslag, D

AU - Indrak, K.

AU - Ossenkoppele, G.J.

AU - de Witte, T.M.

PY - 2012

Y1 - 2012

U2 - https://doi.org/10.3324/haematol.2011.044347

DO - https://doi.org/10.3324/haematol.2011.044347

M3 - Article

C2 - 22102701

SN - 0390-6078

VL - 97

SP - 529

EP - 533

JO - Haematologica

JF - Haematologica

IS - 4

ER -